GlobeNewswire

European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer

Share
  • Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3
  • Treatment with Phesgo is over 90% faster, administered under the skin in just minutes compared to hours with intravenous (IV) infusion of Perjeta plus Herceptin4,5,6
  • Approval is based on results from the pivotal phase III FeDeriCa trial, which showed that Phesgo delivered non-inferior levels of Perjeta and Herceptin in the blood and comparable efficacy and safety versus IV formulations7

Basel, 23 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer.

“This approval represents a significant step forward in the treatment of HER2-positive breast cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “The innovation of Phesgo significantly reduces the time people spend receiving standard of care therapy with Perjeta and Herceptin, helping to minimise the impact of treatment on their everyday lives. It also addresses the increasing demand across healthcare systems for faster and more flexible treatment solutions.”

Phesgo is available as a single-dose vial for SC injection and enables over 90% faster treatment than IV administration of standard of care therapy with Perjeta and Herceptin. SC administration of Phesgo takes approximately eight minutes for the initial loading dose and approximately five minutes for each subsequent maintenance dose. This is compared to approximately 150 minutes for infusion of a loading dose of Perjeta and Herceptin using the standard IV formulations, and between 60-150 minutes for subsequent maintenance infusions of the two medicines.4,5,6

The approval of Phesgo in Europe is based on results from the pivotal phase III FeDeriCa study, which showed that treatment with Phesgo produced non-inferior levels of Perjeta and Herceptin in the blood and demonstrated comparable efficacy versus IV administration of the two medicines. The safety profile of Phesgo with chemotherapy was comparable to IV administration of Perjeta plus Herceptin and chemotherapy. No new safety signals were identified, including no meaningful difference in cardiac toxicity.7

The development of Phesgo highlights Roche's commitment to improving patients’ experience of cancer treatment, looking beyond efficacy outcomes and focusing on more flexible treatment solutions. Phesgo has the potential to help minimise pressure on healthcare systems by reducing administration time, as well as other costs associated with treatment, such as time spent in the infusion chair and drug preparation.8,9 The COVID-19 pandemic has further highlighted the need to utilise novel approaches that help to manage healthcare capacity to free-up time and resources.

About the FeDeriCa study7,10

FeDeriCa is an international, multi-centre, two-arm, randomised, open-label, pivotal phase III study evaluating the pharmacokinetics, efficacy and safety of subcutaneous injection of Phesgo in combination with chemotherapy, compared with standard intravenous (IV) infusions of Perjeta and Herceptin in combination with chemotherapy, in 500 people with HER2-positive early breast cancer treated in the neoadjuvant (before surgery) and adjuvant (after surgery) settings. The primary endpoint of the study is minimum levels of Perjeta in the blood during a given dosing interval (Ctrough), when compared to IV administration of Perjeta. Secondary endpoints include safety; minimum levels of Herceptin in the blood during a given dosing interval (Ctrough); and total pathological complete response, meaning there is no tumour tissue detectable in the tissue removed at the time of surgery.

Data from the FeDeriCa study were presented at the San Antonio Breast Cancer Symposium in December 2019. The FeDeriCa study met its primary endpoint of non-inferior levels of Perjeta in the blood. The geometric mean ratio (GMR; a type of average used when assessing pharmacokinetics) for the primary endpoint was 1.22 (90% CI: 1.14 to 1.31), with the lower limit of the 90% CI of the GMR=1.14≥0.80 (the pre-specified non-inferiority margin). A secondary endpoint of non-inferior levels of Herceptin was also met, with blood concentrations for people receiving Phesgo non-inferior to those receiving IV Herceptin (GMR=1.33 [90% CI: 1.24 to 1.43]; lower limit of 90% CI of GMR=1.24≥0.80). A non-inferiority endpoint was chosen for the study to ensure that people were receiving sufficient dosing with Perjeta and Herceptin as compared to the established IV doses at the same treatment intervals.

About Phesgo
Phesgo combines the same monoclonal antibodies as Perjeta and Herceptin with Halozyme Therapeutics’ Enhanze® drug delivery technology in a novel formulation for subcutaneous (SC) use.4,11  This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.

Halozyme’s Enhanze drug delivery technology may enable and optimise SC drug delivery for appropriate co-administered therapeutics. The technology is based on a proprietary recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that temporarily degrades hyaluronan – a glycosaminoglycan or chain of natural sugars in the body – to aid in the dispersion and absorption of other injected therapeutic drugs.11

Pertuzumab in Phesgo is the same monoclonal antibody as in intravenous (IV) Perjeta, and trastuzumab in Phesgo is the same monoclonal antibody as in IV Herceptin. The mechanisms of action of Perjeta and Herceptin are believed to complement each other as both bind to the HER2 receptor, but in different locations. The combination of Perjeta and Herceptin is thought to provide a more comprehensive, dual blockade of the HER signalling pathways.12,13

Phesgo is approved in the US for the treatment of early and metastatic HER2-positive breast cancer. The approved indications for Phesgo mirror those of Perjeta.

The standard IV formulation of Perjeta in combination with IV Herceptin and chemotherapy (the Perjeta-based regimen) is approved in more than 100 countries for the treatment of both early and metastatic HER2-positive breast cancer. In the neoadjuvant (before surgery) early breast cancer (eBC) setting, the Perjeta-based regimen has been shown to almost double the rate of pathological complete response compared to Herceptin and chemotherapy.14 Additionally, the combination has been shown to significantly reduce the risk of recurrence of invasive disease or death in the adjuvant (after surgery) eBC setting.15 In the metastatic setting, the combination has shown an unprecedented survival benefit in previously untreated (first-line) patients with HER2-positive metastatic breast cancer.16


About Roche’s medicines for HER2-positive breast cancer
Roche has been leading research into the HER2 pathway for more than 30 years and is committed to improving the health, quality of life and survival of people with both early and metastatic HER2-positive disease. HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 25-30% of patients.17 Roche has developed three innovative medicines that have helped transform the treatment of HER2-positive breast cancer: Herceptin, Perjeta and Kadcyla® (trastuzumab emtansine). Eligibility for treatment with Roche’s HER2-targeted medicines is determined via a diagnostic test which identifies people who will likely benefit from these medicines at the onset of their disease.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] O’Shaugnessy J, et al. Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study. Presented at ESMO, 2020 Sept 19-21. Abstract #165MO.
[2]  Xavier P, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962-70.
[3] Tjalma, et al. Trastuzumab IV versus SC: A time, motion and cost assessment in a lean operating day care oncology unit. Presented at: SABCS; 2016 Dec 6-10; San Antonio, TX, USA. Abstract #P4-21-15.
[4] US Food and Drug Administration. Prescribing information for Phesgo. [Internet; cited December 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf.
[5] US Food and Drug Administration. Prescribing Information for Herceptin. [Internet; cited December 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/.
[6] US Food and Drug Administration. Prescribing information for Perjeta. [Internet; cited December 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125409lbl.pdf.
[7] Tan A. et al. Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. Presented at SABCS; 2019 Dec 10-14; San Antonio, Texas. Abstract #PD4-07.
[8] Sripada et al. Subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of metastatic breast cancer in Canada - a budget impact analysis. Presented at SABCS; 2020 Dec 08-11; San Antonio Texas: PS9-55.
[9] Roche data on file.
[10] Clinical trials.gov. A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa). [Internet: December 2020]. Available from: https://clinicaltrials.gov/ct2/show/NCT03493854.
[11] Halozyme. Enhanze® Drug Delivery Technology. [Internet; cited December 2020]. Available from: https://www.halozyme.com/enhanze/overview/default.aspx.
[12] Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748.
[13] Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
[14] Gianni L, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
[15] Minckwitz G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;13;377(2):122-31.
[16] Swain SM, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;19;372(8):724-34.
[17] Jarrett A, et al. Experimentally-driven mathematical modelling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer. Sci Rep. 2019;9:12830.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Heijmans wins 5-year Oost-Nederland waterway maintenance contract26.1.2021 07:30:00 CETPress release

The Dutch Ministry of Public Works and Waterways has awarded Heijmans a five-year contract for the maintenance of waterways in the central-eastern part of the Netherlands (Oost-Nederland). The performance contract covers the Boven-Rijn and Waal rivers and the Maas-Waal canal and represents a value of around € 32 million for Heijmans. Option to extend by three years The contract became definitive on Monday, 25 January. In addition to the initial term of five years, the contract includes an option to extend the contract for an additional term of three years. From Q3 2021, Heijmans will carry out daily work on the above-mentioned waterways. This will include waterway maintenance (dredging), bank maintenance (breakwaters, longitudinal dams, extended banks, bank walls), the maintenance of pavements and moorings in overnight mooring facilities), and the inspection, monitoring and repair of damage and trouble-shooting. Highest score for sustainability When deciding on the tender, the Ministry

Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)26.1.2021 07:02:06 CETPress release

PRESS RELEASE Nyxoah announces full-body 1.5T and 3T MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA) Mont-Saint-Guibert, Belgium – 26th January, 2021 – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE Mark Magnetic Resonance Imaging (MRI) conditional labeling for the current Genio® neurostimulation-based OSA therapy to treat Obstructive Sleep Apnea. This revised labeling ensures that patients who receive the Genio® system and those already implanted can now undergo full-body 1.5T and 3T MRI diagnostic scans within approved parameters and access the benefits of Genio® unique bilateral stimulation therapy. Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “We are delighted to announce full-body 1.5T and 3T MR conditional CE mark approval for t

Dante Labs £30M investment in Cambridge will support global COVID-19 sequencing surveillance program26.1.2021 07:00:00 CETPress release

Dante Labs has already analysed two million and a half COVID-19 RT-PCR tests and sequenced more than 30,000 human whole genomes thanks to its Immensa™ Genome Platform CAMBRIDGE, United Kingdom, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Dante Labs announced today a £30M investment in the United Kingdom to run a global surveillance programme of the new variants of the SARS-CoV-2 virus, starting with a hardware and analytical capacity of 50,000 RNA samples per week. As the SARS-CoV-2 virus mutates, few companies have the skills and expertise to offer both RT-PCR molecular diagnostics and full RNA sequencing. In 2020, Dante Labs successfully leveraged its Immensa™ Genome Platform to support COVID-19 testing at scale, with immediate results. “The SARS-CoV-2 RNA may be simpler to analyse than the human genome. Yet both require massive investments in software and people,” says Dante Labs CEO Andrea Riposati, “Today the UK is the best country to invest in, a global leader in genomics and a beacon of h

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.26.1.2021 07:00:00 CETPress release

Full year net sales from continuing operations¹ up 3% (cc², +3% USD):Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13% cc), Ilaris (+31% cc) and the Xiidra acquisition (+95% cc)Oncology BU grew 3% (cc) driven by Promacta/Revolade (+23% cc), Jakavi (+20% cc), Kisqali (+45% cc), Tafinlar + Mekinist (+16% cc) and Piqray (reaching USD 0.3 billion)Sandoz sales were in line (cc, -1% USD), with Biopharmaceuticals growing 19% (cc) COVID-19 negatively impacted demand, particularly: ophthalmology, dermatology and Sandoz retailCore operating income² grew 13% (cc, +9% USD) and Innovative Medicines and Sandoz core margin improved to 35% and 24% of sales respectively, driven by sales growth, lower spend and productivity Continued transformation of Manufacturing and Business Services contributing to core margin expansion Operating income grew 19% (cc, +12% USD) mainly driven by higher sales and productivity including lower spendNet inco

Juniper Systems Limited Releases New Uinta Software Worldwide26.1.2021 05:16:00 CETPress release

Summary: Uinta™, powerful data collection software from Juniper Systems Limited, is now available throughout EMEA and India, for field crews in asset management, mapping, natural resources, and other industries. BIRMINGHAM, United Kingdom, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Juniper Systems Limited, a manufacturer of rugged handheld computers and GNSS receivers, introduces Uinta™, powerful data collection software for field crews using Microsoft® Windows 10 OS on tablets, who require detailed forms, maps and customisation. Now available throughout Europe, the Middle East, Africa (EMEA), and India, Uinta (yü-ӘN-tah) offers data collection tools such as detailed mapping with points, lines, and areas, form-based notes, and flexibility, delivering a high level of customisation specific to an organisation’s needs. ‘Historically, Juniper Systems has manufactured rugged computer hardware. We’re excited now to offer user-friendly software for many industries, including mapping and asset manageme

PRESS RELEASE: NACON: Q3 2020/21 Sales: 48.7 M€, + 20.3%25.1.2021 17:45:00 CETPress release

Press release Lesquin, 25 January 2021 17:45hrs Q3 2020/21 Sales: 48.7 M€, + 20.3% ·Gaming Accessories : 32.5 M€, + 59% ·Games Back catalogue : 6.9 M€, + 216% ·Confirmation of annual targets IFRS – M€ Sales 2020/2021 2019/2020 Change 1st Quarter 38.0 30.5 + 24.5% 2nd Quarter 48.6 33.2 + 46.4% 3rd Quarter (1) Games Accessories Others (2) 48.7 13.8 32.5 2.3 40.5 17.2 20.5 2.8 + 20.3% - 19.7% + 58.7% - 16.3% Cumulative 31 December (9 months) Games Accessories Others (2) 135.3 46.6 84.1 4.5 104.2 55.0 44.1 5.1 + 29.9% - 15.1% + 90.5% - 10.4% (1) Non audited data (2)Mobile and Audio sales Further strong growth in Q3 2020/21: +20.3% In Q3 2020/21 (1 October to 31 December 2020), Nacon posted 48.7 M€ sales up 20.3%, driven by the performance of RIG® headsets and increased back catalogue sales. GAMES Due to Q3 publishing releases limited to just two new games targetting profitable but narrow niches (Monster Truck®, Handball 21), sales were down by 19.7%. The share of digital sales grew further

PRESS RELEASE: BIGBEN: Cumulative 9 month Sales 2020/21: 223.1 M€ (+ 5%)25.1.2021 17:45:00 CETPress release

Press release Lesquin, 25 January 2021 17:45hrs Cumulative 9 month Sales 2020/21: 223.1 M€ (+ 5%) Q3 Sales showing growth hallmarked by: ·the further momentum of Nacon Gaming ·The limited impact of the 2 nd lockdown in Audio/Telco IFRS – M€ Sales 2020/2021 2019/2020 Change 1st Quarter (April, May, June) Nacon Gaming Bigben Audio / Telco 55.2 38.0 17.2 58.6 30.5 28.1 - 5.8% + 24.5% - 38.7%2nd Quarter (July, Aug., Sept.) Nacon Gaming Bigben Audio / Telco80.6 48.6 32.068.5 33.2 35,3+ 17.7% + 46.4% - 9.4%3rd Quarter (October, Nov., Dec.) (1) Nacon Gaming Bigben Audio / Telco87.3 48.6 38.785.4 40.5 44.9+ 2.3% + 20.3% - 13.9%Cumulative 9 month (Apr-Dec 2020) Nacon Gaming Bigben Audio / Telco223.1 135.3 87.8212.4 104.2 108.2+ 5.0% + 29.9% - 18.9% (1) Non audited data Sales up 2.3% in Q3 2020/21 In Q3 2020/2021 (from October 1 to December 31, 2020), Bigben posted 87.3 M€ sales up 2.3%, driven by the momentum of Nacon Gaming, while the recovery of Audio/Telco was slowed down by the 2nd lockdown